%0 Journal Article
%T Protocol: DuraGraft vascular conduit preservation solution in patients undergoing coronary artery bypass grafting: rationale and design of a within-patient randomised multicentre trial
%A Craig Brown
%A Dave Veerasingam
%A Filippo Cademartiri
%A Garry Cutter
%A Hugues Jeanmart
%A Louis P Perrault
%A Maximilian Y Emmert
%A Nicolas Noiseux
%A Peter Skov Olsen
%A Pierre Voisine
%A Tracy Goeken
%A Vilas Satishchandran
%A Walid Ben Ali
%J Archive of "Open Heart".
%D 2018
%R 10.1136/openhrt-2018-000780
%X Saphenous vein grafts (SVGs) remain the most often used conduits in coronary artery bypass grafting (CABG). However, they are prone to vein graft disease (VGD) during follow-up, which may compromise clinical outcomes. Injury to the SVG endothelium during harvesting and storage promotes neointimal hyperplasia that can advance to atherosclerosis characterised by SVG failure. This trial investigates the potential benefit of DuraGraft, a novel, one-time intraoperative graft treatment developed to efficiently protect the structural and functional integrity of the vascular endothelium, on the development and progression of VGD in CABG patients
%K saphenous vein graft
%K vein graft failure
%K myocardial infarction
%K coronary artery bypass grafting
%K patency
%K vein graft treatment
%K endothelial damage inhibitor
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5905829/